The selective P-TEFb inhibitor CAN508 targets angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Small molecule inhibitors of cyclin-dependent kinases (CDK) are utilized in cancer therapy for their cytostatic and cytotoxic effects.
• Some CDK inhibitors also demonstrate anti-angiogenic properties, crucial for tumor growth and metastasis.
• Angiogenesis, the formation of new blood vessels, is a critical process in cancer progression.

Purpose of the Study:

• To investigate the anti-angiogenic potential of the 3,5-diaminopyrazole compound CAN508.
• To determine the molecular mechanisms underlying CAN508's effects on endothelial cells and cancer cells.
• To evaluate P-TEFb as a potential therapeutic target for anti-angiogenic cancer therapy.

Main Methods:

• Assessing the effect of CAN508 on endothelial cell migration and tube formation in vitro.
• Measuring the impact of CAN508 on RNA polymerase II C-terminal phosphorylation and mRNA synthesis in endothelial cells.
• Analyzing CAN508's effect on vascular endothelial growth factor (VEGF) expression in human cancer cell lines.
• Evaluating the selectivity of CAN508 towards the positive transcriptional regulator P-TEFb.

Main Results:

• CAN508 significantly inhibited endothelial cell migration and tube formation, key processes in angiogenesis.
• CAN508 reduced RNA polymerase II C-terminal phosphorylation and mRNA synthesis in endothelial cells.
• CAN508 demonstrated high selectivity for the positive transcriptional regulator P-TEFb.
• CAN508 decreased vascular endothelial growth factor (VEGF) expression in multiple human cancer cell lines.

Conclusions:

• CAN508 exhibits potent anti-angiogenic activity by inhibiting endothelial cell functions essential for blood vessel formation.
• The mechanism involves the inhibition of P-TEFb, leading to reduced mRNA synthesis and VEGF expression.
• P-TEFb represents a promising molecular target for the development of novel anti-angiogenic cancer therapies.